DE60118763D1 - Verfahren zur diagnose und behandlung von huntingtonserkrankung - Google Patents
Verfahren zur diagnose und behandlung von huntingtonserkrankungInfo
- Publication number
- DE60118763D1 DE60118763D1 DE60118763T DE60118763T DE60118763D1 DE 60118763 D1 DE60118763 D1 DE 60118763D1 DE 60118763 T DE60118763 T DE 60118763T DE 60118763 T DE60118763 T DE 60118763T DE 60118763 D1 DE60118763 D1 DE 60118763D1
- Authority
- DE
- Germany
- Prior art keywords
- disease
- treatment
- adenosine
- inhibit
- huntington
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010000117 Abnormal behaviour Diseases 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 102000030621 adenylate cyclase Human genes 0.000 abstract 2
- 108060000200 adenylate cyclase Proteins 0.000 abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003040 circulating cell Anatomy 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI002137A IT1318960B1 (it) | 2000-10-03 | 2000-10-03 | Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. |
| PCT/EP2001/011425 WO2002029408A2 (en) | 2000-10-03 | 2001-10-03 | Methods for diagnosing and treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60118763D1 true DE60118763D1 (de) | 2006-05-24 |
Family
ID=11445897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60118763T Expired - Lifetime DE60118763D1 (de) | 2000-10-03 | 2001-10-03 | Verfahren zur diagnose und behandlung von huntingtonserkrankung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040023312A1 (de) |
| EP (1) | EP1325335B1 (de) |
| AT (1) | ATE323287T1 (de) |
| AU (1) | AU2002213990A1 (de) |
| DE (1) | DE60118763D1 (de) |
| IT (1) | IT1318960B1 (de) |
| WO (1) | WO2002029408A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375194B2 (en) | 2002-01-28 | 2008-05-20 | California Institute Of Technology | Antibodies that bind to an epitope on the Huntington's disease protein |
| US20040049484A1 (en) * | 2002-09-11 | 2004-03-11 | Hamano Life Science Research Foundation | Method and apparatus for separating and extracting information on physiological functions |
| US8318446B2 (en) | 2008-12-05 | 2012-11-27 | California Institute Of Technology | DNA-damage-induced proteolysis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9819382D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
-
2000
- 2000-10-03 IT IT2000MI002137A patent/IT1318960B1/it active
-
2001
- 2001-10-03 AU AU2002213990A patent/AU2002213990A1/en not_active Abandoned
- 2001-10-03 DE DE60118763T patent/DE60118763D1/de not_active Expired - Lifetime
- 2001-10-03 WO PCT/EP2001/011425 patent/WO2002029408A2/en active IP Right Grant
- 2001-10-03 US US10/398,499 patent/US20040023312A1/en not_active Abandoned
- 2001-10-03 AT AT01982391T patent/ATE323287T1/de not_active IP Right Cessation
- 2001-10-03 EP EP01982391A patent/EP1325335B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040023312A1 (en) | 2004-02-05 |
| WO2002029408A2 (en) | 2002-04-11 |
| IT1318960B1 (it) | 2003-09-19 |
| ITMI20002137A0 (it) | 2000-10-03 |
| WO2002029408A3 (en) | 2002-12-12 |
| ITMI20002137A1 (it) | 2002-04-03 |
| EP1325335A2 (de) | 2003-07-09 |
| EP1325335B1 (de) | 2006-04-12 |
| ATE323287T1 (de) | 2006-04-15 |
| AU2002213990A1 (en) | 2002-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taggart et al. | Some effects of motor-car driving on the normal and abnormal heart | |
| Lancranjan et al. | Reproductive ability of workmen occupationally exposed to lead | |
| Silveira et al. | Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze | |
| Przelomski et al. | Eastern equine encephalitis in Massachusetts: a report of 16 cases, 1970–1984 | |
| Suhr | Executive functioning deficits in hypothetically psychosis-prone | |
| Stone et al. | Retinal abnormalities in the Siamese cat | |
| DK1421215T3 (da) | Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA | |
| DE602005024810D1 (de) | Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung | |
| Smits et al. | Apraxia in mild cognitive impairment and Alzheimer's disease: validity and reliability of the Van Heugten test for apraxia | |
| WO2005098429A3 (en) | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | |
| Zager et al. | Maternal immune activation in late gestation enhances locomotor response to acute but not chronic amphetamine treatment in male mice offspring: role of the D1 receptor | |
| Brines et al. | Quantitative Autoradiographic Analysis of lonotropic Glutamate Receptor Subtypes in Human Temporal Lobe Epilepsy: Up‐regulation in Reorganized Epileptogenic Hippocampus | |
| ATE323287T1 (de) | Verfahren zur diagnose und behandlung von huntingtonserkrankung | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| NO20014969L (no) | Diagnose av en persons risiko for utvikling av aterosklerose eller diabetisk retinopati | |
| Marek et al. | Genetic influences on brain stimulation-produced analgesia in mice. I. Correlation with stress-induced analgesia | |
| RU2256399C1 (ru) | Способ диагностики скрытой артериальной гипертензии | |
| Premalatha et al. | Assessment of Nipah virus transmission among pork sellers in Seremban, Malaysia | |
| Cruz‐Martínez et al. | Clinical, genetic and electrophysiologic correlation in hereditary neuropathy with liability to pressure palsies with involvement of PMP22 gene at chromosome 17p11. 2 | |
| GJÖRSTRUP | Effects of some α‐adrenoceptor stimulating and blocking agents on the salivary amylase secretion in the rabbit | |
| DE60127935D1 (de) | Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie | |
| Scott-Orr et al. | Estimation of direct and indirect losses due to Johnes disease in New South Wales, Australia | |
| Maynard et al. | The acoustic startle reflex in Sprague-Dawley rats is altered by permanent middle cerebral artery occlusion | |
| EP3322817A1 (de) | Oligonucleotide und deren verwendung | |
| Egejuru et al. | Onchocercal Skin Disease Profiles Following Ivermectin Treatment in the Middle Imo River Baisn, Nigeria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |